TAVO-101

N/A

Report date: 2024/04/23 17:57:44

Base Information

Drug NameTAVO-101
Drug Alias NameTAVO-101TAVO101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionThymic stromal lymphopoietin modulators
TargetsThymic stromal lymphopoietin
Therapy Area/IndicationsHypersensitivityDermatitis, Atopic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNew ZealandAustralia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesTavotek Biotherapeutics (Hong Kong) Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTavotek BiotherapeuticsTavotek Biotherapeutics (Hong Kong) Ltd
Inactive CompaniesN/A
Active IndicationsHypersensitivityDermatitis, Atopic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A